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Linagliptin (LGT) is a member of the class of gliptins that inhibit the enzyme dipeptidyl-peptidase-4. They are used to 
reduce glucose blood levels in patients with type 2 Diabetes mellitus. Due to its recent development and launching on the 
market, LGT has no official compendium monograph, national or international, or available registries for the qualitative 
determination of this drug. The objective of this work was to characterize LGT by using thermal techniques, nuclear 
magnetic resonance, mass and infrared spectrometry, liquid chromatography and ultraviolet spectrophotometry to be used 
as a chemical reference substance. The range and melting point obtained are in accordance with that described in the 
literature. The main groups of LGT molecule were observed in infrared spectroscopy and the molecular ion m/z 473.25 
ratio was found in mass spectroscopy analysis. In UV spectroscopy, the maximum wavelength absorption of the substance 
in different solvents can be observed. The chromatographic methods provide selectivity for LGT and can be used to analyze 
it qualitatively. The proposed conditions have been successfully applied for identification and qualitative analysis of LGT 
as a chemical reference substance, contributing to studies of this gliptin, and to the quality control of medicines that contain 
it. 
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Introduction 
 
It is essential to know the physicochemical 
properties of active substances in order to 
develop pharmaceuticals and medications (1). 
For this purpose, it is necessary to characterize 
the raw material in order to ensure the substance 
properties, lot by lot, including the 
identification of the different crystalline forms 
of the substance (polymorphisms) (2). 
Chemical Reference Substances (CRS) are 
certified reference materials used to evaluate 
conformity of the pharmaceutical inputs and 
medications (3). They are substances, or in a 
few cases a mixture of substances, established 
or distributed by pharmacopeias or authorized 
official public institutions, with a high degree 
of purity and uniformity. They are intended for 
use in chemical and physical tests and assays, 
in which their properties are compared to those 
of the products that are being analyzed (3). The 
non-compendial standards of reference are 
substances with a high degree of purity that can 
be obtained through private suppliers and 
should be characterized in order to ensure their 
identity, potency and purity. 
The linagliptin utilized in this study belong 
to the class of gliptins that act by inhibiting the 
dipeptylpeptidase IV (DPP-IV). When this 
enzyme is inhibited, the active principle 
prevents the destruction of the incretins (GLP-
1 and GIP), hormones that stimulate pancreas to 
produce insulin when the glucose level in the 
blood is high. In addition, gliptins reduce the 
glucagon levels in patients who do not manage 
to attain the ideal glucose levels by diet and 
exercise (4). Currently the pharmaceuticals that 
are part of this class are sitagliptin phosphate, 
vildagliptin, saxagliptin, alogliptin and 
linagliptin (5). 
Among the thermal analyses, Differential 
Scanning Calorimetry (DSC) is a well-
consolidated technique to analyze substance 
purity (6). The method evaluates the purity of 
the compound using an analysis of the fusion 
peak obtained, applying the Van’t Hoff fusion 
point law of depreciation, which foresees the 
reduction of the pure compound fusion point 
due to the presence of impurities  (7). 
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Another technique that is used to 
characterization of a substance is the infrared 
spectrophotometry. It supplies evidence of the 
presence of several functional groups in the 
organic structure due to the interaction of the 
molecules or atoms with electromagnetic 
radiation in a molecular vibration process (8). 
The infrared radiation corresponds to the part of 
the electromagnetic spectrum between the 
visible and microwave regions. Together with 
the Nuclear Magnetic Resonance (NMR) it can 
help identify unknown compounds (8,9). 
According to Hardy (10), “NMR 
designates the resonating interaction of the 
dipole moment of the magnetic nucleus μ in an 
external magnetic field with an electromagnetic 
field”. This energy modifies the nucleus spin 
when the sample is exposed on a magnetic field 
to obtain the latter’s magnetic moment. Since 
each nucleus has a different magnetic moment, 
it is possible to determine its kind of chemical 
bond (11). 
Other qualitative methods that can be used 
to characterize substance samples are 
spectrophotometry in UV-Visible region and 
High Performance Liquid Chromatography 
(HPLC). The spectrophotometry in UV-Visible 
is a simple method much used to control the 
quality of pharmaceutical products due to the 
potential of the great majority of the 
pharmaceuticals for absorbing energy in these 
regions (12). HPLC, a very used technique for 
this purpose, is a type of chromatography that 
uses small columns, filled with specially 
prepared materials and a mobile phase that elute 
under high pressures.  It is able to perform 
separations and quantitative analyses of many 
compounds present in various kinds of samples, 
on a time scale of a few minutes, with high 
resolution, efficiency and sensibility (12,13).  
In recent years, analyses by Ultra 
Performance Liquid Chromatography with 
ultraviolet and mass spectrometry detection 
(UPLC-UV/MS) has been proposed as a 
strategy to shorten the time of analysis, 
collecting both non fragmented and fragmented 
ions, which may be consecutively utilized to 
quantify and inform about the ion fragments 
(14,15). MS analysis simultaneously supplies 
measures of exact mass and information 
regarding fragmentation by collecting data, 
using alternative low and high-energy parallel 
collision to acquire the spectrum. 
Considering all the commented techniques, 
the objective of this study was to identify and 
characterize linagliptin CRS performing 
thermal analysis as fusion point and 
Differential Exploratory Calorimetry (DSC), 
infrared spectroscopy (IR), hydrogen and 
carbon NMR, UV/Visible spectrophotometry, 
HPLC-UV and UPLC with mass detection.  
 
Experimental 
 
Linagliptin samples 
 
The linagliptin (CRS) used as reference 
was acquired from Sequoia Research Products 
(United Kingdom) with a stated content of 
99.24 %, control number 12030114271, as 
specified in the analysis certificate. 
 
Equipments 
 
The equipments used in this study were 
Mettler Toledo, model FP 90 for fusion point 
analysis, Koffler equipment, Wagner & Muniz 
brand for melting range, Mettler Toledo 
equipment, model DSC1 with heat flow, 
infrared spectroscopy (Perkin Elmer 
equipment, model Spectrum BXII), hydrogen 
and carbon nuclear magnetic resonance (Varian 
equipment, model VNMRS-300 with 300 
MHz), UV/VIS spectrophotometer (Shimadzu 
equipment, model UV1601 PC), high 
performance liquid chromatographer 
(Shimadzu equipment, model CBM 20A) and 
ultra perfomance liquid chromatographer 
(UPLC equipment Waters® Acquity coupled to 
Micdromass Q-TOF micro mass spectrometer). 
 
Melting Point 
 
The identification of the melting point was 
performed by capillary method in a Mettler 
Toledo equipment previously calibrated. A 
LGT CRS sample was packed in a capillary 
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tube (1 mm – diameter; 75 mm - length) that 
was heated at 10 °C / minute. The analysis was 
done in triplicate.  
For determination of melting range of the 
LGT, a Koffler equipment was used. A small 
amount of sample was placed on a blade and 
covered with a cover slip. Upon heating, the 
LGT crystals began to liquefy, forming droplets 
that were observed under the microscope. 
Within seconds, the sample was completely 
liquefied.  
 
Differential Exploratory Calorimeter 
 
Analyzes were carried out at in an 
exploratory differential calorimeter by heat 
flow. A 1.95 mg LGT CRS was weighed into 
40 μL aluminum crucible which was sealed and 
subjected to analysis. The initial studies were 
performed in a heating ramp of 10 °C / minute, 
with a temperature range of 30 to 300 °C and 
flow of N2 of 50 mL/min. 
 
Infrared Spectrophotometer 
 
A small amount of the LGT SQR sample 
was placed at the specific site of the equipment 
and the reading performed, since this model of 
equipment does not require preparation of KBr 
pellets. 
 
Nuclear Magnetic Resonance 
 
The basic structural analysis by 1H and 13C 
NMR it were made in a Varian apparatus using 
deuterated dimethylsulfoxide (DMSOd6) as 
solvent. 
 
Linagliptin characterization by UV, HPLC and 
UPLC 
 
Four solvents (acetonitrile (ACN), water, 
ethanol and methanol) were chosen for this 
characterization, by analyzing LGT by 
scanning the 200 to 400 nm range. The analyses 
were performed in quartz cuvettes with 10 mm 
optical path.  
The chromatograms were obtained in a 
high performance liquid chromatograph, with 
an injection of 40 μL of the solutions in an 
Agilent® Zorbax C8 column (150 mm x 4.6 mm 
x 5 μm) with the oven temperature at 30 °C and 
mobile phase consisting of water with the 
addition of 1.0% triethylamine (TEA) (pH 4.5, 
adjusted with orthophosphoric acid): ACN 
(80:20, v/v). 
For UPLC method, the mobile phase 
employed was formic acid 0.1% (pH 3.5 
adjusted with ammonium hydroxide) and 
methanol (50:50, v/v), oven temperature 30 °C, 
0.2 mL/min flow and injection volume 2 μL. 
The run time was 4 minutes in an Agilent® C18 
Eclipse Plus RRHD column (50 mm x 2.1 mm 
x 1.8 μm).  The profile of the molecular break 
of the analyte (MM = 472.23 g/mol) was 
performed using the positive MS/MS 
electrospray technique. 
 
Results and Discussion 
 
The fusion point found was 205.2 °C and 
the melting range observed for LGT was 202 - 
205 °C. Light brown liquefaction was observed, 
formed between the slide and the laminule in 
the Koffler equipment, indicating sample 
degradation. The results found by Mettler 
Toledo and Koffler methods showed similar 
values among themselves and close to the value 
of 202 °C described in the literature (16). These 
methods can be used to help identify the LGT.  
The methodology used to perform DSC 
analysis is described in Standard ASTM E 928-
03 (6). By analyzing the results of the heating 
curve of DSC (Figure 1), it was found that an 
endothermal event occurred at 60.26 °C 
characteristic of desolvatation, followed by 
another endothermal event of fusion at 203.92 
°C. Later, an exothermal event followed, with 
fusion enthalpy (ΔH) of 183.12 J/g, with 
degradation at 245.02 °C. The value obtained 
for fusion is close to the 202 °C described by 
the literature (16). The degradation event was 
also observed in obtaining the melting range 
using the Koffler method. 
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Figure 1 Heating curve of  LGT CRS obtained by DSC. 
 
Based on the information supplied by the 
IR spectrum of LGT (Figure 2), Table 1 was 
elaborated to summarize the main absorption 
bands obtained. The characteristic bands of 
LGT were identified based on the literature 
(8,11,17-19). 
 
Table 1 Interpretation of the main bands of the IR spectrum of LGT CRS. 
Wave number 
(cm-1) Attribution 
3356.41 N–H Stretching the piperidinea 
2848.81 and 
2922.82 –NH2 Primary amine
a 
2233.63 –C≡C–  Characteristic of ethyneb 
1652.43 and 
1697.81 
NH
N
O
O
CH3
N
H
N
 
Characteristic of 
carbonyl in purine ringd 
1511.34 
N
N
 
Quinazoline clusterc 
1398.53 and 
1347.48 C–N 
Axial deformation of 
aromatic tertiary aminee 
1128.47 
NH
NH2 
Aminopyridine clustera 
758.48 N–H  
Absorption of bonds 
outside the plane 
betwen nitrogen and 
hydrogenb 
aCHAVES, 2011; bPAVIA, 2001; cCULBERTSON, 1952; dLISTER, 1971; 
eSILVERSTEIN, 2007 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Spectrum in the IR region of linagliptin CRS. 
 
The bands found correspond to the main 
functional clusters of LGT, confirming the 
identity of the sample acquired. In the analysis 
by RMN1H and RMN13C,   the resulting spectra 
are demonstrated in Figures 3 and 4, 
respectively. 
 
 
 
 
 
 
 
 
Figure 3 Spectrum of RMN1H of LGT CRS in DMSOd6 solvent at 400 MHz. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Spectrum of RMN13C of LGT CRS in DMSOd6 solvent at 100 MHz. 
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The assignments of the spectrum of 
RMN1H and RMN13C of LGT CRS are shown 
in Tables 2 and 3, respectively. The analyses of 
the assignments of hydrogens and carbons were 
determined based on the literature (8,11,20). 
The results obtained allowed the identification 
of the LGT, since the signals agree with the 
assignments expected for the pharmaceutical 
that is being analyzed.  
 
Table 2 Assignments of RMN1H spectrum obtained by analyzing LGT CRS in 
DMSOd6. 
Position Chemical Shift (ppm) Multiplicity 
Number of 
hydrogens Assignment 
5, 15 1.75 – 1.79 Singlet 6H CH3 
- 2.49 – 2.51 Multiplet - Solvent (water) 
6, 9, 14 2.80 – 2.90 Multiplet 6H CH2 
11 3.26 Singlet 1H CH 
- 3.32 – 3.34 Multiplet - Solvent (DMSOd6) 
8, 10, 
12 3.35 – 3.36 Multiplet 6H CH2 
13 4.88 – 4.91 Duplet 2H NH2 
7 5.32 Singlet 3H CH3 
2 7.65 – 7.70 Triplet 1H CH aromatic ring 
1 7.79 – 7.83 Duplet 1H CH aromatic ring 
3 7.88 – 7.94 Triplet 1H CH aromatic ring 
4 8.23 – 8.27 Duplet 1H CH aromatic ring 
 
 
Table 3 Assignments of the spectrum of RMN13C obtained by analysis of LGT 
CRS in DMSOd6. 
Position Chemical shift (ppm) Interpretation 
21 3.57 CH3 
25 22.06 CH3 
15. 16. 17. 19 22.06 – 35.98 4 (CH2) 
- 39.26 – 40.61 Solvent (dmsod6) 
20  46.04 N – CH3 
22. 18 47.76 – 50.07 N – CH2  
9 57.99 N – CH2 
23. 24 74.25 – 81.62  C ≡ C 
14 103.69 3N – C 
12. 13 122.95 – 126.18 – C = C – N 
10. 11 127.60 – 128.33 2 (CON) 
8 134.54 1 C aromatic 
1. 2. 3. 4. 5. 6 148.19 – 169.31 6 C aromatic 
 
After the LGT was identified, it was 
characterized by UV absorption 
spectrophotometry. The UV spectra obtained in 
the different solvents are shown in Figure 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Comparison of the UV spectra of LGT CRS in different solvents at a  
concentration of 10 μg/mL. 
 
 
According to the spectra, two maximums 
of LGT absorption can be observed around 226 
nm and 293 nm. Methanol is the solvent used to 
extract LGT from the pharmaceutical form in 
papers published in the literature (21,22,23). 
However, the greatest absorptivity was 
obtained in the two maximum wavelengths for 
the solvents acetonitrile and ethanol. 
LGT was also evaluated using 
chromatographic methods aiming to look at 
substance purity. Figure 6 shows the 
chromatogram by HPLC of the pharmaceutical 
with a retention time of 6.47 minutes at a 
concentration of 10 μg/mL. The suitability 
parameters of the system were obtained and the 
values found were k’ equal to 4.04; tail factor 
equal to 1.23; theoretical plates equal to 4842. 
Peak purity can be evaluated using LC-Solution 
software and the results obtained indicate that 
the method was selective for the substance 
tested. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Linagliptin chromatogram with retention time in 6.47 minutes. Peak 
purity and UV spectrum were evaluated. Suitability parameters of the system: 
k’= 4.04, tail factor=1.23, theoretical plates=4842. 
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The qualitative method by the UPLC 
proposed supplied a retention time of 1.36 
minutes, and was also selective for the LGT 
substance. The chromatogram obtained, as well 
as the UV spectrums acquired by the diode 
array detector UV spectrum are shown in 
Figure 7.  
As in the method by HPLC, the separation 
was efficient for LGT. The qualitative method 
developed also allowed the analysis of the mass 
spectrum of the analyte. The result is in figure 
7.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 (a) LGT chromatogram at a concentration of 20 μg/mL with respective 
UV spectrum in the method using UPLC; (b) Mass spectrum of LGT and majority 
breakdown profile. 
 
 
 
The mass spectrum confirms the presence 
of LGT in the solution by recording the 
molecular ion   m/z 473.2555 ratio according to 
what is expected for LGT. The method 
proposed proves effective to characterize the 
LGT. The majority breakdown profile indicates 
molecular ions with a ratio of m/z 420.2087 and 
m/z 403.1850 which can be explained by the 
loss of the 2,3-butino and primary amine 
clusters, respectively.  
 
Conclusions 
 
The thermal behavior of LGT CRS per 
fusion point, melting range and DSC was 
important to identify and evaluate the sample 
purity, presenting fusion point and melting 
range close to the value described in the 
literature.  
The characteristic absorption bands of 
LGT obtained by IR analysis supplied 
information needed to identify the sample. 
Additionally, the data obtained in the spectrum 
of RMN1H and RMN13C provided the 
characteristic signals of hydrogens and carbons 
of the molecule. Furthermore, the results 
obtained from mass spectrum provided the 
mass load ratio attributed to LGT, besides the 
major degradation profile of the molecule. The 
UV spectrophotometric method allowed 
obtaining the maximums and minimums of 
absorption of LGT. The chromatographic 
methods by HPLC and UPLC enabled the 
identification of LGT through the retention 
times and UV spectrum obtained. The identity 
of the material acquired has been confirmed and 
it is possible to affirm that this chemical 
reference substance can be used in later 
qualitative and quantitative studies.   
Therefore, the proposed conditions were 
successfully applied for identification and 
qualitative analysis of LGT as a chemical 
reference substance, contributing to studies of 
this gliptin, and to the quality control of 
medicines that contain it. 
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